Autifony Therapeutics Ltd. is developing compounds for hearing loss and tinnitus that modulate potassium channel Kv3, a target on inhibitory receptors of the CNS that may affect central auditory processing of speech and other sounds.

Age- or noise-related hearing loss may occur as a result of either cochlear damage that reduces signal transduction to the brain or deterioration of central auditory processing and cognitive decline that hinder interpretation of the remaining signal.